High resolution PVC and PVC reduced with Bu,SnH. The reduction is never complete and CHzCl groups preferentially remain. It causes almost complete formation of cyclopentane structures from both internal and chain end unsaturation. as chain end unsaturation except if there are interferences with initiator residues : in that case, its combination with chain end unsaturation. By the last method short branches and long ends are determined. Residual primary chlorine in all kinds of branches (methyl, ethyl, butyl, long ends) is taken into account. Long end contents are to be corrected (factor around 1.5), due to incomplete relaxation in standard analysis conditions. 'H NMR of reduced PVC can be used to get the total non-reduced structures, both -CH,Cl and -CHCl-. PVC was prepared by suspension or solution (trichlorobenzene) polymerization at 55' C,using dicetyl peroxydicarbonate as an initiator. The initiator residue content is higher in suspension PVC at very low conversion, and then levels off at a low value : in solution polymerization, it chiefly depends on the monomer/initiator ratio. At low conversion, more chain end and less short branches are present in suspension polymerization. Otherwise, only the butyl branch content shows a definite trend to increase with conversion. In solution polymerization, the number of defects is chiefly dependent on the initial monomer concentration : it is generally much higher than in suspension, except for the chloromethyl branches where both processes give about the same results.'H and 13C NMR data were obtained on 'H NMR gives total unsaturation as well 13C NMR of reduced PVC gives the
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.